MOSAIC
FOLFOX as Adjuvant Therapy in Stage II/III Colon Cancer
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 2,246 patients with resected stage II/III colon cancer, adjuvant FOLFOX4 improved disease-free survival compared with 5-FU/leucovorin.
N
2.246
Design
Open-label RCT
Endpunkt
3-year disease-free survival
Relevanz
1
Ergebnis3-yr DFS 78.2% vs 72.9% (HR 0.77, P=0.002). 6-yr OS in stage III 72.9% vs 68.7% (HR 0.80, 95% CI 0.65-0.97, P=0.023); no OS benefit in stage II.
André T, et al. N Engl J Med. 2004;350(23):2343-2351; André T, et al. J Clin Oncol. 2009;27(19):3109-3116. 10.1056/NEJMoa032709
Diskussion & Kritik
Established oxaliplatin-based adjuvant therapy in stage III colon cancer. Stage II remains case-by-case, weighted by clinical and molecular risk features.